Compare Merck & Co., Inc. (MRK) vs Spotify Technology (SPOT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Spotify Technology — how do they compare? Merck & Co., Inc. trades at $126.24 (market cap $307.25B), while Spotify Technology trades at $492.88 (market cap $101.23B). The key difference: Merck & Co., Inc. is far larger — about 3× Spotify Technology's market cap, and Merck & Co., Inc. pays a 2.73% dividend while Spotify Technology pays none. Which is the better fit depends on your goals.
| MRK | SPOT | |
|---|---|---|
Market Cap | $307.25B | $101.23B |
Sector | Health | Media |
52-Week High | $129.52 | $738.53 |
52-Week Low | $77.60 | $412.75 |
Enterprise Value | $350.66B | $91.81B |
Dividend Yield | 2.73% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $126.27, down 0.96% on the day, with a neutral technical signal and strong fundamental performance. The company reported robust 2025 results with $65.01B revenue and $18.25B net income, beating EPS estimates in recent quarters. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while analyst consensus remains bullish with a $137.30 price target.
Outlook is positive driven by earnings momentum and strategic M&A, but risks include patent expirations and competitive pressures. The stock offers a dividend yield with upcoming payment, supporting income investors. Valuation multiples are elevated, requiring sustained growth to justify current levels amid macroeconomic uncertainties.
Spotify (SPOT) trades at $493.23, up 3.16% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with support at $481 and resistance at $500. Fundamentally, revenue grew to $17.19B in 2025 with net income surging to $2.21B, reflecting improved profitability. Recent developments include AI feature expansions and parent-managed accounts for free users, enhancing growth prospects.
Outlook remains positive with analyst consensus target at $617, though rich valuation (P/E 33.54) and competition pose risks. Earnings growth and AI integration present opportunities, but investors should monitor execution against high expectations and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Spotify Technology
Spotify Technology S.A. provides music streaming services. The Company offers commercial-free music and ad-supported services to subscribers. Spotify Technology serves clients worldwide.
Read more on SPOT →
